undamentalytics Newsletter
Sign in

Decoy Therapeutics Inc. insider trading

Every open-market purchase and sale by Decoy Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $19,750 2 trades by 2 insiders 3 months later: median +6.4% (+1.2% vs S&P 500) Insider sales, 5 years $17 1 trade by 1 insider 3 months later: median −16.0% (−10.9% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Decoy Therapeutics Inc.’s insiders pay?

From July 27, 2015 to November 20, 2025, 14 insiders reported 57 open-market purchases and 3 sales not made under a pre-set plan in Decoy Therapeutics Inc. Twelve months after each purchase was reported, the shares were −64.5% against the S&P 500 on average (median −77.2%), over 49 purchases with a full year of prices; 0% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 28, 2015 into $2,920 by November 2, 2026, −10.4% a year. It held shares 20% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,512 (+4.6% a year), and held throughout $43,453 (+14.0%).

$0$20.0k$40.0k 201520172019202120232025 $43.5k$16.5k$2.9k
Copying Decoy Therapeutics Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Decoy Therapeutics Inc.'s insiders from July 28, 2015, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 20% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Westphal Christoph H and related entities President and CEO 44 −63.2% (44) 0% 1 — October 18, 2018
Boston Foundation, Inc. 10% owner 0 — — 2 — January 10, 2019
Rosenblum Mark J Exec VP Finance, CFO 2 — — 0 — November 20, 2025
Arthur David J. Chief Executive Officer 1 — — 0 — March 9, 2022
Hanish Arnold C Director 1 — — 0 — November 26, 2019
Jordan Scott Chief Business Officer 1 — — 0 — February 18, 2020
Kozin Marc D Director 1 −51.4% (1) 0% 0 — November 23, 2015
Mackinnon Roderick Director 1 −81.0% (1) 0% 0 — March 15, 2016
Mccreedy Bruce J JR. Director 1 — — 0 — February 12, 2020
Mcvicar William K. Director 1 — — 0 — February 12, 2020
Northrup Jonathan P Director 1 — — 0 — February 12, 2020
Sculley John Director 1 −85.6% (1) 0% 0 — July 12, 2016
Stacy Michelle Director 1 −79.6% (1) 0% 0 — March 16, 2016
Wessel Thomas Chief Medical Officer 1 −81.0% (1) 0% 0 — March 15, 2016

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Decoy Therapeutics Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Decoy Therapeutics Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −21.0% against the index. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
July 29, 20162 buying−56.1%−68.4%−80.1%
March 31, 20165 buying−5.4%−1.6%−75.9%
November 30, 20152 buying−34.6%+6.9%−56.6%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Decoy Therapeutics Inc. · Funds · Politicians